{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:58:32Z","timestamp":1787795912549,"version":"build-2784847793"},"reference-count":13,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2022,11,2]]},"DOI":"10.1080\/14712598.2022.2143262","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T09:10:06Z","timestamp":1667293806000},"page":"1339-1343","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?"],"prefix":"10.1080","volume":"22","author":[{"given":"Sheila A","family":"Doggrell","sequence":"first","affiliation":[{"name":"School of Pharmacy and Medical Sciences, Griffith University, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201904"},{"key":"cit0002","unstructured":"Mayo Clinic. Multiple sclerosis. 2022. cited 2022 Oct 25] Available 2022 Oct 25 from https:\/\/www.mayoclinic.org\/diseases-conditions\/multiple-sclerosis\/symptoms-causes\/syc-20350269"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014656"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00209-5"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005516"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520918375"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11118-7"},{"key":"cit0010","unstructured":"ClinicalTrials.gov. An extension study of ublituximab in participants with relapsing multiple sclerosis. 2022. cited 2022 Sept 15]. Available from 2022 Sept 15: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04130997?term=ublituximab&draw=2&rank=1"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104002"},{"key":"cit0012","unstructured":"Multiple Sclerosis News Today. FDA decision on ublituximab for relapsing MS pushed to year\u2019s end. 2022. cited 2022 Sept 20]. Available from 2022 Sept 20: https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2022\/06\/01\/fda-decision-ublituximab-relapsing-ms-pushed-back-years-end\/"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104109"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2022.2143262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T14:39:43Z","timestamp":1687617583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2022.2143262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,2]]}},"alternative-id":["10.1080\/14712598.2022.2143262"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2022.2143262","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}